ide397
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 14, 2021 (NCT04794699)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
MAT2A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07277413 | Phase 1 | Dec 15, 2025 | IDEAYA Biosciences |
| NCT05975073 | Phase 1/Phase 2 (Phase 2) | Jul 27, 2023 | Amgen |
| NCT04794699 | Phase 1 | Apr 14, 2021 | IDEAYA Biosciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| IDEAYA Biosciences | For profit | 2 | 2 | 1 | 2021 |
| Amgen | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1